DOCSLIB.ORG

(Ikervis) in the Management of Ocular Surface Inflammatory Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(Ikervis) in the Management of Ocular Surface Inflammatory Diseases Clinical science Br J Ophthalmol: first published as 10.1136/bjophthalmol-2020-317907 on 9 March 2021. Downloaded from Real- world experience of using ciclosporin- A 0.1% (Ikervis) in the management of ocular surface inflammatory diseases Rashmi Deshmukh ,1 Darren Shu Jeng Ting,1,2 Ahmad Elsahn,1,2 2 1,2 1,2 Imran Mohammed , Dalia G Said, Harminder Singh Dua 1Ophthalmology, Nottingham ABSTRACT is being recognised.5 Many factors operate in the University Hospitals NHS Trust, Purpose To report the real- world experience of using aetiology and pathophysiology of DED of which Nottingham, Nottinghamshire, UK topical ciclosporin, Ikervis, in the management of ocular inflammation was first recognised as an important 2Academic Ophthalmology, surface inflammatory diseases (OSIDs). and consistent component in the report published Division of Clinical Methods This was a retrospective study of patients following a Delphi approach to treatment recom- Neurosciences, University of treated with Ikervis for OSIDs at the Queen’s Medical mendations in 20066 and substantiated in subse- Nottingham, Nottingham, Centre, Nottingham, between 2016 and 2019. Relevant 7 8 Nottinghamshire, UK quent reports. data, including demographics, indications, clinical Steroids have been the mainstay in the manage- Correspondence to parameters, outcomes and adverse events, were collected ment of most inflammatory conditions, including Professor Harminder Singh and analysed for patients who had completed at least 6 DED, allergic eye disease (AED), chemical eye Dua, Ophthalmology, University months follow-up . For analytic purpose, clinical outcome injury, ocular mucous membrane pemphigoid of Nottingham, Nottingham, was categorised as ’successful’ (resolved or stable Nottinghamshire, UK; (OMMP), Steven-Johnson syndrome (SJS) and disease), ’active disease’ and ’drug intolerance’. 9 harminder. dua@ nottingham. many others. However, over the last two decades, ac. uk Results 463 patients were included; mean age was non- glucocorticoid immune- modulators, especially 51.1±21.6 years, with a 59.0% female predominance. ciclosporin A (CsA), have gained prominence as RD and DSJT contributed Mean follow-up was 14.6±9.2 months. The most steroid- sparing topical therapy for DED.10 11 Oil- equally. common diagnosis was dry eye disease (DED; 322, based CsA preparations were in vogue (Optim- 69.5%), followed by allergic eye disease (AED; 53, Received 3 September 2020 mune 0.2%, licenced for dogs) and used off- label 11.4%) and ocular mucous membrane pemphigoid/ Revised 11 February 2021 in humans since the 1980s. Restasis (0.05% CsA, Accepted 17 February 2021 Steven- Johnson syndrome (OMMP/SJS; 38, 8.2%). Allergan, California, USA) was approved and Successful treatment was achieved in 343 (74.1%) licenced by the Food and Drug Administration patients, with 44 (9.5%) requiring additional treatment 12 and 76 (16.4%) reporting drug intolerance. The efficacy (FDA), USA, for treatment of DED in 2002. of Ikervis was highest in DED (264, 82.0%), followed by However the drug was not available in Canada OMMP/SJS (25, 65.8%) and post- and Europe including the UK, and the market keratoplasty (7, 50.0%; http://bjo.bmj.com/ p<0.001). Logistic regression analysis demonstrated authorisation application to the European Medi- age <70 years (p=0.007), AED (p=0.002) and OMMP/ cines Agency (EMA) was withdrawn by Allergan in 13 SJS (p=0.001) as significant predictive factors for Ikervis 2018. In 2015 Ikervis, a CsA eye- drop prepara- intolerance. AED and post- keratoplasty were 8.16 times tion (1 mg/mL or 0.1%) was approved by the EMA (95% CI, 2.78 to 23.99) and 13.98 times (95% CI, 4.22 for the treatment of severe DED in adults and by to 46.28), respectively, more likely to require additional the National Institute for Health and Care Excel- treatment compared with DED. lence, UK, for the treatment of severe keratitis of on September 26, 2021 by guest. Protected copyright. Conclusions Ikervis is a useful steroid-sparing topical DED not responding to treatment with tear substi- treatment for managing OSIDs in the real- world setting. tutes.14 15 In 2018, the same preparation of CsA Preparations with improved tolerability are needed to as in Ikervis (recommended once daily for DED) benefit a larger number of patients. was marketed with a different packaging, under the name of Verkazia (recommended four times a day) after being approved by EMA for treatment of 16 INTRODUCTION severe vernal keratoconjunctivitis (VKC). Dry eye disease (DED) is the most common disease As the only licenced steroid-sparing anti- © Author(s) (or their affecting the ocular surface (OS) in the young and inflammatory agent available for direct treatment at employer(s)) 2021. Re- use old, increasing with age, with a female prepon- the OS, the incentive and clinical pressure to use permitted under CC BY- NC. No derance.1 2 There are various reports on the inci- it for other inflammatory conditions was consider- commercial re- use. See rights able, and as often happens in clinical practice, off- and permissions. Published dence and prevalence of DED, which is estimated by BMJ. to affect 15%–33% of individuals aged over 65 label use of Ikervis became an option in a variety of years but younger individuals are increasingly clinical scenarios where previous oil- based prepa- To cite: Deshmukh R, being affected.2–4 DED is traditionally classified as rations of CsA were used with some or significant Ting DSJ, Elsahn A, et al. 17 18 Br J Ophthalmol Epub ahead aqueous deficient DED (resulting from affection of benefit. We report our real- world experience of print: [please include Day the lacrimal gland) or evaporative DED (primarily with licenced and off-label use of Ikervis in the Month Year]. doi:10.1136/ due to meibomian gland dysfunction), though management of chronic non- infective OS inflam- bjophthalmol-2020-317907 increasingly a considerable overlap between the two matory diseases (OSIDs). Deshmukh R, et al. Br J Ophthalmol 2021;0:1–6. doi:10.1136/bjophthalmol-2020-317907 1 Clinical science Br J Ophthalmol: first published as 10.1136/bjophthalmol-2020-317907 on 9 March 2021. Downloaded from MATERIALS AND METHODS Table 1 Summary of the characteristics of patients treated with A list of patients who received a prescription of Ikervis (topical topical ciclosporin (Ikervis) in Nottingham, UK CsA 0.1%) from April 2016 to October 2019 was obtained from the hospital pharmacy database. All the charts were retrospec- Total n=463 tively analysed and patients who had a follow-up of more than Parameters n (%) 6 months were included in the study. An Excel spreadsheet was Age, years created to standardise the data collection, which included the 0–18 34 (7.3) demographic profile, diagnosis, clinical parameters, dose and >18 to 30 44 (9.5) duration of Ikervis treatment and clinical outcome. Diagnosis >31 to 50 98 (21.2) was based on clinical examination, characteristic findings and >51 to 70 152 (32.8) biopsy (where applicable). Patients were categorised into DED, >70 135 (29.2) AED including VKC and atopic keratoconjunctivitis (AKC), Gender OMMP, SJS and post- keratoplasty cases. Diagnoses other than these were categorised as ‘others’. These patients included non- Female 273 (59.0) specific chronic conjunctivitis, limbal stem cell deficiency, neuro- Male 190 (41.0) trophic keratopathy, inflammatory keratitis like superior limbic Diagnosis keratitis, inflamed pterygium or pseudopterygium, peripheral Dry eye diseases 322 (69.5) ulcerative keratitis and scleritis/episcleritis. Clinical parameters AED 53 (11.4) noted included best corrected visual acuity at baseline and final OMMP 28 (6.0) follow- up visit or at the time of discontinuing Ikervis, whichever Post- corneal graft 14 (3.0) was sooner, intraocular pressure, conjunctival findings, corneal SJS 10 (2.2) findings, dry eye parameters like tear-film breakup time and Others* 36 (7.8) Schirmer’s test II values were recorded. A note was made when CDVA, logMAR patients presented with burning sensation or ocular discomfort Baseline 0.24±0.45 affecting compliance. When Ikervis was discontinued by the Final 0.23±0.47 treating physician within a duration of 6 months, owing to the Clinical outcome† side effects or patient intolerance, patients were not excluded Resolved 119 (25.7) but were categorised under the intolerant group when evaluating Stable 224 (48.4) the clinical outcome. Active 44 (9.5) Clinical outcome was defined based on clinical parameters Intolerant to Ikervis 76 (16.4) on follow- up as: (1) resolved: when the signs and symptoms Treatment frequency subsided completely for at least 1 month with no requirement Once a day 286 (61.8) of further Ikervis treatment; (2) stable: when the disease did not resolve nor worsened with ongoing Ikervis and the OS (defined Twice a day 173 (37.4) as the conjunctiva, cornea and lacrimal apparatus) was free from >Twice a day 4 (0.9) visibly detectable inflammation and/or graft rejection (in post- Follow- up duration, months 14.6±9.2 keratoplasty cases); (3) active: flare up of condition or active *Included cases of inflammatory keratitis (n=9), non- specific chronic conjunctivitis inflammation requiring additional treatment such as topical (n=7), scleritis/episcleritis (n=4), limbal stem cell deficiency (n=3), neurotrophic http://bjo.bmj.com/ steroids and (4) intolerant: when patient on Ikervis experienced keratopathy (n=2), pseudopterygium (n=2), peripheral ulcerative keratitis (n=2), superior limbic keratoconjunctivitis (n=2), uveitis (n=2), epithelial ingrowth (n=1), burning sensation and discomfort necessitating discontinuation conjunctival granuloma (n=1) and giant papillary conjunctivitis (n=1). of the drug. The treatment was considered a ‘success’ if outcome †Clinical outcome is defined as: (1) resolved: resolution of disease without further 1 (resolved) or outcome 2 (stabilised) were achieved. need of Ikervis; (2) stable: stable disease with ongoing Ikervis; (3) active: active disease requiring additional treatment such as topical steroids and (4) intolerant: Ikervis discontinued due to intolerable side effects.
Load more

Recommended publications
  • Scleral Faqs
    www.scleralcenter.com SCLERAL FAQS CONTACT US: Office: 501 E. Palm Valley Blvd. WHY ARE SCLERAL LENSES SO Round Rock, TX 78664 COMFORTABLE? Website: www.scleralcenter.com Scleral lenses vault over the cornea and rest on Phone: 512.248.2424 the white portion of the eye (sclera), which is less sensitive. They fit under the eyelid, resulting in comfort & stability. JAVIER R. ZAMORA, OD Dr. Zamora is the co-founder of Advanced Eye Care & Surgery and has been fitting specialty contact lenses since 1998. He is a graduate of the University of Texas at Austin and the University of Houston College of Optometry. FIRM LENSES LARGER LENSES Sharp Vision Comfort & Stability DEBBIE A. ZAMORA, OD Dr. Zamora is the co- founder of Advanced Eye WHY DO SCLERAL LENSES OFFER Care & Surgery and has SUPERIOR VISION? been fitting specialty contact lenses since They are manufactured in Gas Permeable (GP) 2001. She is a graduate HOW material which provides a smooth optical surface of Tulane University and the University of Houston and excellent vision even if your cornea has an College of Optometry. SCLERAL LENSES irregular shape. Scleral lenses treat astigmatism and are available with bifocal options. CAN HELP YOU DEBRA A. WARE, OD WHAT IS THE ‘LIQUID BANDAGE’ Dr. Ware has been fitting EFFECT? specialty contact lenses since 1998. She is Scleral lenses provide extra moisture for healthy a graduate of Baylor eyes, as well as for patients with severe dry eyes. University and the The space between your eye and the back of the University of Houston scleral lens acts as a fluid reservoir that provides College of Optometry.
    [Show full text]
  • Dry Eye in Patient with Clinical History of Chronic Blepharitis and Chalaziosis Edited by Dr
    year 10 num b e r 2 4 e y e d o c t o r m a r ch- a p r i l 2018 CLINICAL CASES OF LUCIO BURATTO Dry eye in patient with clinical history of chronic blepharitis and chalaziosis edited by Dr. Maria Luisa Verbelli, Dr.Alessia Bottoni Observation and 1 anamnesis Arrives at our observation at CIOS, Italian Center for Dry Eye at CAMO, a 56-year-old patient with blepharitis, redness, ocular burning and abundant mucous secretion present in both eyes. Furthermore, an enlarged lymph node is seen in the right laterocervical site. At ocular anamnesis the patient reports chronic blepharitis from the juvenile age, multiple chalazion in both eyes, an operation for right Fig. 1 Handpiece for the application of the pulsed light of the Eye-Light instrument upper eyelid chalaziosis in 2006 (4 upper eyelid chalazion , 3 in the lower); negative anamnesis for these pathologies in the family. The patient is shortsighted since adolescence, has not had any other eye operations and has no ocular allergies. The general anamnesis does not report major systemic diseases or medication intake. On objective examination of the anterior segment we find bilaterally: reduced lacrimal meniscus, posterior blepharitis, obstruction of all the Meibomian glands of the upper and lower eyelids, conjunctival hyperemia with dry spots, transparent cornea, transparent crystalline. The no contact tonometry is 15 mmHg in RE, 16 mmHg in LE. The OCT of the macula does not show changes in both eyes. The BUT is 4.9 seconds in RE, and 15.6 seconds in LE.
    [Show full text]
  • Surgically Induced Scleral Staphyloma
    Original Article Surgically induced scleral staphyloma Yong Yao1, Ming-Zhi Zhang1, Vishal Jhanji1,2 1Joint International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou 515041, China; 2Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China Contributions: (I) Conception and design: Y Yao; (II) Administrative support: MZ Zhang; (III) Provision of study materials or patients: Y Yao; (IV) Collection and assembly of data: Y Yao; (V) Data analysis and interpretation: Y Yao; V Jhanji; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Yong Yao. Shantou International Eye Center, Jinping District, Guangxia New Town, Shantou 515041, China. Email: [email protected] or [email protected]. Background: To report the clinical features of surgically induced scleral staphyloma and investigate the management. Methods: Retrospective uncontrolled study. Results: A full ophthalmological evaluation of surgically induced scleral staphyloma in four patients was performed. The first patient was a 3-year-old young girl underwent corneal dermoid resection. The second patient was a 60-year-old man underwent nasal pterygium excision and conjunctival autograft without Mitomycin C (MMC). The other two were respectively a 74-year-old woman and a 69-year-old man underwent cataract surgery. All patients performed allogeneic sclera patch graft. In the at least half a year follow-up, the best corrected visual acuity (BCVA) of all the four patients were no worse than that of preoperative. Ocular symptoms disappeared, including eye pain, foreign body sensation, and so on. Unfortunately, the fourth patient showed sclera rejection and partial dissolution at postoperative 1 month.
    [Show full text]
  • Long-Term Ocular Surface Stability in Conjunctival Limbal Autograft Donor Eyes
    CLINICAL SCIENCE Long-Term Ocular Surface Stability in Conjunctival Limbal Autograft Donor Eyes Albert Y. Cheung, MD,*† Enrica Sarnicola, MD,*†‡ and Edward J. Holland, MD*† (OSST) procedures can provide healthy limbal stem cells Purpose: fi – To investigate the incidence of limbal stem cell de ciency and conjunctiva to rehabilitate a damaged ocular surface.2 8 (LSCD) in donor eyes after conjunctival limbal autograft (CLAU). Conjunctival limbal autograft (CLAU) is a technique that ; Methods: An observational retrospective review was performed on transplants a portion (typically 3to6clockhours)ofthe all patients who underwent CLAU alone, combined keratolimbal healthy stem cells from an unaffected eye to the contralat- allograft with CLAU (“Modified Cincinnati Procedure”), or com- eral affected eye in individuals affected by unilateral LSCD.6 bined living-related conjunctival limbal allograft (lr-CLAL) with 7 $ Cultivated limbal epithelial transplantation (CLET) CLAU having 6 months of follow-up after surgery. The outcome 8 measures were best-corrected visual acuity (BCVA) and ocular and simple limbal epithelial transplantation (SLET) provide surface status. ex vivo and in vivo expansion of stem cells, respectively, to repopulate the ocular surface. In contrast to CLET and SLET, Results: The inclusion criteria were fulfilled by 45 patients. Of CLAU is ideal for rehabilitating severe unilateral LSCD these, 26 patients underwent CLAU, 18 underwent combined requiring combined conjunctival limbal transplantation and keratolimbal allograft/CLAU, and 1 underwent combined lr- for reconstruction of the ocular surface. Proponents of CLET CLAL/CLAU. Mean age at the time of surgery was 39.6 years. and SLET have raised concerns regarding the potential Mean logMAR preoperative BCVA was 20.08.
    [Show full text]
  • Managing Ocular Surface Inflammation”
    E Y 7th EDITION OLOGIES OF THE E OLOGIES OF th H 7 AT EDITION P THEA INTERNATIONAL CONTEST OF CLINICAL CASES IN PATHOLOGIES OF THE EYE THEA INTERNATIONAL CONTEST OF CLINICAL CASES IN PATHOLOGIES OF THE EYE NTEST OF CLINICAL CASES IN OF CLINICAL NTEST O This brochure is produced under the sole responsibility of the authors. Laboratoires Théa are not involved in the writing of this document. This brochure may contain MA off-label and/or not validated by health authorities information. NATIONAL C NATIONAL R HEA INTE HEA T 2018 - 2019 EDITION 2018 - 2019 EDITION MANAGING MANAGING OCULAR SURFACE OCULAR SURFACE INFLAMMATION THE BEST CLINICAL CASES FROM 22 COUNTRIES INFLAMMATION THE BEST CLINICAL CASES FROM 22 COUNTRIES WWW.THEA-TROPHY.COM CLINICAL CASES CLINICAL - BA WTROBRO0120 WWW.THEA-TROPHY.COM Laboratoires Théa • 12, rue Louis Blériot 63017 Clermont-Ferrand Cedex 2 • France T +33 4 73 98 14 36 Laboratoires Théa F +33 4 73 98 14 38 LABORATOIRES-THEA.COM th 7 EDITION This brochure is produced under the sole responsibility of the authors, Laboratoires Théa are not involved in the writing of the clinical cases. This brochure may contain MA off-label and/or not validated by health authorities information. PREFACE Mr. JEAN-FRÉDÉRIC CHIBRET TROPHY 2018-2019 the Clinical Cases 2 M. Jean-Frédéric CHIBRET President of Laboratoires Théa Théa has focused its activities on research, development and commercialization of eye-care products, but at the same time has invested in education and knowledge promotion in line with the strong Chibret family tradition. In this way, Théa supports many projects and educational activities such as the European Meeting of Young Ophthalmologists (EMYO) or its partnership with the European Board of Ophthalmology (EBO).
    [Show full text]
  • Amniotic Membrane Grafts in Pediatric Corneal Limbal Dermoids with Conjunctival Eyelashes: a Case Presentation
    Open Journal of Ophthalmology, 2016, 6, 191-197 http://www.scirp.org/journal/ojoph ISSN Online: 2165-7416 ISSN Print: 2165-7408 Amniotic Membrane Grafts in Pediatric Corneal Limbal Dermoids with Conjunctival Eyelashes: A Case Presentation Larisa Akah Che1, Linda A. Morgan2, Donny W. Suh2,3 1University of Nebraska Medical Center, Omaha, NE, USA 2Children’s Hospital & Medical Center, Omaha, NE, USA 3Department of Ophthalmology and Visual Sciences, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA How to cite this paper: Che, L.A., Morgan, Abstract L.A. and Suh, D.W. (2016) Amniotic Mem- brane Grafts in Pediatric Corneal Limbal Purpose: To report a case of a pediatric corneal limbal dermoid with eyelashes and Dermoids with Conjunctival Eyelashes: A to describe post-operative changes after excision with reconstruction using amniotic Case Presentation. Open Journal of Oph- membrane grafting, sutures and fibrinogen-thrombin glue. Case Report: One pedia- thalmology, 6, 191-197. http://dx.doi.org/10.4236/ojoph.2016.64027 tric patient was identified with a grade II infratemporal corneal-limbal dermoid with conjunctival eyelashes. The dermoid was surgically excised and the cornea recon- Received: August 23, 2016 structed with amniotic membrane using sutures and fibrinogen/thrombin glue. Pre- Accepted: October 11, 2016 operative and postoperative measurement of astigmatism, anisometropia and pres- Published: October 14, 2016 ence of exposure keratopathy were performed. Copyright © 2016 by authors and Scientific Research Publishing Inc. Keywords This work is licensed under the Creative Commons Attribution International Corneal Limbal Dermoid, Amniotic Membrane Graft, Choriostoma License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ Open Access 1.
    [Show full text]
  • Transglutaminase in Ocular Health and Pathological Processes
    perim Ex en l & ta a l ic O p in l h t C h f Journal of Clinical & Experimental a Tong et al. J Clinic Experiment Ophthalmol 2011, S:2 o l m l a o n l DOI: 10.4172/2155-9570.S2-002 r o g u y o J Ophthalmology ISSN: 2155-9570 ResearchResearch Article Article OpenOpen Access Access Recent Advances: Transglutaminase in Ocular Health and Pathological Processes Louis Tong1,2,3*, Evelyn Png2, Wanwen Lan2 and Andrea Petznick2 1Singapore National Eye Center, Singapore 2Singapore Eye Research Institute, Singapore 3Duke-NUS Graduate Medical School, Singapore Abstract Transglutaminase (TG) is a diverse class of crosslinking enzymes involved in the regulation of cytokine production, endocytosis, cell adhesion, migration, apoptosis and autophagy. It has been implicated in inflammatory diseases, neurodegenerative processes and cancer. The eye is a specialized organ which subserves the important function of vision and has distinctive physiological and anatomical properties that differ from other body tissues. Understanding of the roles of various TGs in the eye therefore require studies specific to cells and tissues of ocular origin. We review the advances in TG research in ocular diseases, including pterygium, glaucoma, cataract and proliferative vitreoretinopathy. TG1 is a molecule important for keratinisation in many cicatrizing diseases of the ocular surface, including keratoconjunctivitis sicca. TG2, with multiple functions, has been shown to be important in inflammation and cell adhesion in various ocular diseases. The results of TG research in each region of the eye are critically assessed and the implications of these studies in the treatment of ocular diseases are discussed.
    [Show full text]
  • Scleral Lenses and Eye Health
    Scleral Lenses and Eye Health Anatomy and Function of the Human Eye How Scleral Lenses Interact with the Ocular Surface Just as the skin protects the human body, the ocular surface protects the human Scleral lenses are large-diameter lenses designed to vault the cornea and rest on the conjunctival tissue sitting on eye. The ocular surface is made up of the cornea, the conjunctiva, the tear film, top of the sclera. The space between the back surface of the lens and the cornea acts as a fluid reservoir. Scleral and the glands that produce tears, oils, and mucus in the tear film. lenses can range in size from 13mm to 19mm, although larger diameter lenses may be designed for patients with more severe eye conditions. Due to their size, scleral lenses consist SCLERA: The sclera is the white outer wall of the eye. It is SCLERAL LENS made of collagen fibers that are arranged for strength rather of at least two zones: than transmission of light. OPTIC ZONE The optic zone vaults over the cornea CORNEA: The cornea is the front center portion of the outer Cross section of FLUID RESERVOIR wall of the eye. It is made of collagen fibers that are arranged in the eye shows The haptic zone rests on the conjunctiva such a way so that the cornea is clear. The cornea bends light the cornea, overlying the sclera as it enters the eye so that the light is focused on the retina. conjunctiva, and sclera as CORNEA The cornea has a protective surface layer called the epithelium.
    [Show full text]
  • Ethical Issues in Living-Related Corneal Tissue Transplantation
    Viewpoint Ethical issues in living-related corneal J Med Ethics: first published as 10.1136/medethics-2018-105146 on 23 May 2019. Downloaded from tissue transplantation Joséphine Behaegel, 1,2 Sorcha Ní Dhubhghaill,1,2 Heather Draper3 1Department of Ophthalmology, ABSTRact injury, typically chemical burns, chronic inflamma- Antwerp University Hospital, The cornea was the first human solid tissue to be tion and certain genetic diseases, the limbal stem Edegem, Belgium 2 transplanted successfully, and is now a common cells may be lost and the cornea becomes vascula- Faculty of Medicine and 5 6 Health Sciences, Dept of procedure in ophthalmic surgery. The grafts come from rised and opaque, leading to blindness (figure 1). Ophthalmology, Visual Optics deceased donors. Corneal therapies are now being In such cases, standard corneal transplants fail and Visual Rehabilitation, developed that rely on tissue from living-related donors. because of the inability to maintain a healthy epithe- University of Antwerp, Wilrijk, This presents new ethical challenges for ophthalmic lium. Limbal stem cell transplantation is designed to Belgium 3Division of Health Sciences, surgeons, who have hitherto been somewhat insulated address this problem by replacing the damaged or Warwick Medical School, from debates in transplantation and donation ethics. lost limbal stem cells (LSC) and restoring the ocular University of Warwick, Coventry, This paper provides the first overview of the ethical surface, which in turn increases the success rates of United Kingdom considerations generated by ocular tissue donation subsequent sight-restoring corneal transplants.7 8 from living donors and suggests how these might Limbal stem cell donations only entail the removal Correspondence to be addressed in practice.
    [Show full text]
  • Frequency and Risk Factors of Symptomatic Dry Eye Disease at Tertiary Care Eye Hospital, Karachi
    Biostatistics and Biometrics Open Access Journal ISSN: 2573-2633 Research Article Biostat Biometrics Open Acc J Faisal’s Issue - January 2018 Copyright © All rights are reserved by Muhammad Faisal Fahim DOI: 10.19080/BBOAJ.2018.04.555639 Frequency and Risk Factors of Symptomatic Dry Eye Disease at Tertiary Care Eye Hospital, Karachi Shaheerah Gul1, Adil Salim Jafri1, Muhammad Faisal Fahim2* 1Department of Ophthalmology, Al-Ibrahim Eye Hospital, Pakistan 2Department of Research & Development, Al-Ibrahim Eye Hospital, Pakistan Submission: November 27, 2017; Published: January 19, 2018 *Corresponding author: Muhammad Faisal Fahim, M.Sc (Statistics), Statistician, Research & Development Department, Al-Ibrahim Eye Hospital, Isra postgraduate Institute of Ophthalmology, Karachi, Pakistan, Tel: ; Email: Abstract Objective: To determine frequency and risk factors of symptomatic dry eye disease at tertiary care eye hospital, Karachi. Material & Methods: This was a descriptive cross sectional study carried out at Al-Ibrahim Eye Hospital, Isra postgraduate Institute of Oph- thalmology, Karachi from March to October 2016. Non-Probability purposive sampling technique was used for data collection. Inclusion criteria give consent. Symptoms of dry eye were assessed using Tear breakup test (TBUT) test. SPSS version 20.0 was used to analyze data. were patients aged ≥ 21 years and on the basis of dry eye symptoms. Exclusion criteria were other systemic eye disease and those who did not Results: A total of 100 patients 65 female and 35 male were diagnosed with dry eye syndrome. The age group of 21-30 years having the high- est frequency of 34 patients, whereas after the 50 years of age the frequency of patients decreases to 21.
    [Show full text]
  • Blepharitis Last Revised in October 2015
    Menu Sign in (https://accounts.nice.org.uk/signin) Search... Blepharitis Last revised in October 2015 Changes Back to top Last revised in October 2015 October 2015 — reviewed. A literature search was conducted in October 2015 to identify evidence­ based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No changes to clinical recommendations have been made. Previous changes Back to top September 2012 — reviewed. A literature search was conducted in September 2012 to identify evidence­based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations have been made. April 2011 — minor update. Change to recommendation regarding need for additional contraception during or after a course of tetracycline ­ additional contraception is no longer required when using antibiotics that are not enzyme inducers with combined hormonal methods for durations of 3 weeks or less [FSRH, 2011 (/blepharitis#!references/­315093)]. Issued in June 2011. March 2011 — topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made. September 2010 — minor update. Hydromoor® (hypromellose 0.3% preservative­free single dose eye drops) have been included. Issued in September 2010. March 2010 — minor update. Lubri­Tears® eye ointment has been discontinued. Prescription removed. Issued in March 2010. December 2007 to May 2008 — converted from CKS guidance to CKS topic structure. The evidence­ base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The clinical scenario structure has been reviewed.
    [Show full text]
  • 29 Yo White Female
    5/21/2014 29 yo white female CC: Decreased VA OD X few days Women of Vision Present Are We PMHx: 5 months pregnant at Risk for Vision Morbidity MODERATOR BVA: 20/30 OD 20/20 OS Pupils: (-) APD Louise Sclafani O.D. Louise A. Sclafani, OD, FAAO CF: FTFC OD/OS Co-instructors: Jill Autry, OD, Melissa Associate Professor Barnett, OD, Susan Cotter, OD, Diana University of Chicago Hospital Shechtman, OD GOALS It’s a BOY… • Our panel will take on this challenge and discuss this population as it relates to the following conditions optic neuritisOCT Women at Risk: Retinal Issues Fetus maculopathy??? evaluation, AMDnutritional controversy, psychosocial issuesmanagement options with strabismus, ocular concerns for common Diana Shechtman, OD systemic pharmaceuticals, safety issues with [[email protected]] ophthalmic drugs, and the hormonal influence Associate Professor of Optometry at on ocular surface disease NOVA Southeastern University College of Optometry Courtesy of Dr. M Rafieetary CASE PRESENTATION SUMMARY So why would’t ICSC (idiopathic central serous chorioretinopathy) WE (female gender) be stressed out? Serous macular detachment due to RBR breakdown • As ODs we need to place a higher priority on those individuals at increased risk for vision- threatening ocular disease. It has been estimated that the female gender represents 23 of all visually compromised individuals due to inherent risk factors and lack of access to healthcare. Diana Shechtman OD FAAO 1 5/21/2014 Hyperpermeability at RPE site is associated with choroidal Which of the following drugs in Not associated CSR in women circulation disruption/vascular congenstion with ICSC? Quillen et al.
    [Show full text]